Format

Send to

Choose Destination
Semin Cancer Biol. 2019 Aug 21. pii: S1044-579X(19)30110-5. doi: 10.1016/j.semcancer.2019.08.024. [Epub ahead of print]

The adjuvant treatment revolution for high-risk melanoma patients.

Author information

1
Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
2
Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: paola.queirolo@hsanmartino.it.

Abstract

The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives.

KEYWORDS:

Melanoma; adjuvant; immunotherapy; neoadjuvant; targeted therapy

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center